Supplemental HIV Testing Market Woes Force FDA To Consider Other Options
This article was originally published in The Gray Sheet
Executive Summary
The financial instability of Calypte Biomedical over the past several months has increased FDA's interest in licensing alternative approaches for confirmatory HIV testing for blood banks, including nucleic acid testing
You may also be interested in...
HIV test shortage
Calypte Biomedical's April announcement of possible bankruptcy triggers CDC's May 10 warning of potential U.S. shortage of supplemental tests kits for confirmatory testing of HIV antibodies in specimens derived from patients or blood donors. Distributor bioMérieux has notified customers of a halt in Cambridge Biotech HIV-1 Western blot kit shipments. CDC and FDA have contacted other HIV test-makers, including BioRad Laboratories and OraSure, about ramping up kit production. Labs experiencing shortage should contact CDC at 404-639-4581...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.